In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Larimar Therapeutics Inc (NASDAQ: LRMR) closed at $3.9 down -2.74% from its previous closing price of $4.01. In other words, the price has decreased by -$2.74 from its previous closing price. On the day, 1.11 million shares were traded. LRMR stock price reached its highest trading level at $4.12 during the session, while it also had its lowest trading level at $3.85.
Ratios:
For a deeper understanding of Larimar Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.46 and its Current Ratio is at 5.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on January 29, 2025, initiated with a Buy rating and assigned the stock a target price of $18.
On October 16, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $26.
On October 03, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $22.Wedbush initiated its Outperform rating on October 03, 2024, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 31 ’25 when Flynn James E bought 9,375,000 shares for $3.20 per share. The transaction valued at 30,000,000 led to the insider holds 9,538,945 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LRMR now has a Market Capitalization of 333802560 and an Enterprise Value of 199892528.
Stock Price History:
The Beta on a monthly basis for LRMR is 0.92, which has changed by -0.5006402 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, LRMR has reached a high of $9.50, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is 18.05%, while the 200-Day Moving Average is calculated to be 6.76%.
Shares Statistics:
For the past three months, LRMR has traded an average of 1.36M shares per day and 2093440 over the past ten days. A total of 64.03M shares are outstanding, with a floating share count of 35.96M. Insiders hold about 57.99% of the company’s shares, while institutions hold 42.28% stake in the company. Shares short for LRMR as of 1753920000 were 6365303 with a Short Ratio of 4.69, compared to 1751241600 on 6262837. Therefore, it implies a Short% of Shares Outstanding of 6365303 and a Short% of Float of 11.18.
Earnings Estimates
The current rating of Larimar Therapeutics Inc (LRMR) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.37 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.59 and -$1.76 for the fiscal current year, implying an average EPS of -$1.7. EPS for the following year is -$1.78, with 7.0 analysts recommending between -$1.18 and -$2.37.
